JP7276664B2 - 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法 - Google Patents

細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法 Download PDF

Info

Publication number
JP7276664B2
JP7276664B2 JP2019524319A JP2019524319A JP7276664B2 JP 7276664 B2 JP7276664 B2 JP 7276664B2 JP 2019524319 A JP2019524319 A JP 2019524319A JP 2019524319 A JP2019524319 A JP 2019524319A JP 7276664 B2 JP7276664 B2 JP 7276664B2
Authority
JP
Japan
Prior art keywords
cells
mesenchymal stem
stem cells
subject
allogeneic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534307A5 (fr
JP2019534307A (ja
Inventor
ジョシュア エム． ハレ，
アナ マリー ランディン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of JP2019534307A publication Critical patent/JP2019534307A/ja
Publication of JP2019534307A5 publication Critical patent/JP2019534307A5/ja
Priority to JP2022065222A priority Critical patent/JP7491964B2/ja
Application granted granted Critical
Publication of JP7276664B2 publication Critical patent/JP7276664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
JP2019524319A 2016-11-11 2017-11-10 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法 Active JP7276664B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022065222A JP7491964B2 (ja) 2016-11-11 2022-04-11 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421048P 2016-11-11 2016-11-11
US62/421,048 2016-11-11
PCT/US2017/061031 WO2018089752A1 (fr) 2016-11-11 2017-11-10 Procédés d'utilisation de cellules souches mésenchymateuses humaines pour induire une immunité cellulaire et humorale

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022065222A Division JP7491964B2 (ja) 2016-11-11 2022-04-11 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法

Publications (3)

Publication Number Publication Date
JP2019534307A JP2019534307A (ja) 2019-11-28
JP2019534307A5 JP2019534307A5 (fr) 2020-12-17
JP7276664B2 true JP7276664B2 (ja) 2023-05-18

Family

ID=60655047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524319A Active JP7276664B2 (ja) 2016-11-11 2017-11-10 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
JP2022065222A Active JP7491964B2 (ja) 2016-11-11 2022-04-11 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022065222A Active JP7491964B2 (ja) 2016-11-11 2022-04-11 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法

Country Status (11)

Country Link
US (1) US20190290698A1 (fr)
EP (1) EP3538114A1 (fr)
JP (2) JP7276664B2 (fr)
KR (1) KR20190084091A (fr)
CN (1) CN110691600B (fr)
AU (1) AU2017358042A1 (fr)
CA (1) CA3043594A1 (fr)
IL (1) IL266561B2 (fr)
TW (2) TW201831681A (fr)
WO (1) WO2018089752A1 (fr)
ZA (1) ZA201903574B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7491964B2 (ja) 2016-11-11 2024-05-28 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019374898A1 (en) * 2018-11-08 2021-06-24 University Of Miami Method of determining responsiveness to cell therapy in dilated cardiomyopathy
CN111568927A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节记忆b细胞数量的应用
KR20230066407A (ko) 2020-09-08 2023-05-15 롱에버론 인코포레이티드 동종이계 중간엽 줄기 세포를 이용한 알츠하이머병 치료
WO2023009537A1 (fr) 2021-07-26 2023-02-02 Longeveron Inc. Utilisation de cellules souches mésenchymateuses dans le traitement du syndrome du cœur gauche hypoplasique juvénile
AU2022343620A1 (en) 2021-09-10 2024-01-18 Longeveron Inc. Treatment of aging frailty comprising administering bone marrow derived mesenchymal stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536860A (ja) 2010-08-31 2013-09-26 クック・ジェネラル・バイオテクノロジー・エルエルシー 動物の疾病の治療のための全身的、同種間幹細胞治療
JP2016516985A (ja) 2013-03-15 2016-06-09 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP977899A0 (en) * 1999-04-15 1999-05-13 Monash University Improvement of t cell mediated immunity
WO2006124827A2 (fr) * 2005-05-13 2006-11-23 University Of Miami Dissection moleculaire de reponses cellulaires a un alloantigene ou un auto-antigene dans un rejet de greffe et une maladie auto-immune
EP1937309A4 (fr) * 2005-09-14 2010-01-20 Univ Columbia Lymphocytes t cd8+ régulateurs induits par des anticorps anti-cd3
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
AU2009259053B2 (en) 2008-06-13 2013-12-12 University College Cardiff Consultants Limited Novel adult progenitor cell
CN101690731B (zh) * 2009-09-09 2013-07-10 中国人民解放军海军总医院 脐带华通胶源间充质干细胞在制备心力衰竭细胞移植材料中的应用
JP5333508B2 (ja) * 2011-04-22 2013-11-06 コニカミノルタ株式会社 画像処理システム、ジョブ実行方法およびジョブ実行プログラム
CN102908364A (zh) * 2012-11-14 2013-02-06 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗儿童扩张型心肌病药物中的应用
KR20150111945A (ko) * 2013-01-04 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트 관련 완제의 특성조사
WO2014203267A2 (fr) * 2013-06-17 2014-12-24 Kasiak Research Pvt. Ltd. Procédé pour l'isolement, la purification et la mise à l'échelle industrielle de cellules souches mésenchymateuses dérivées du tissu adipeux humain
US20190224240A1 (en) * 2016-01-11 2019-07-25 Cardiocell, Llc Cell therapy for the treatment of non-ischemic heart failure
CN110691600B (zh) 2016-11-11 2024-04-16 美商生命科学有限公司 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536860A (ja) 2010-08-31 2013-09-26 クック・ジェネラル・バイオテクノロジー・エルエルシー 動物の疾病の治療のための全身的、同種間幹細胞治療
JP2016516985A (ja) 2013-03-15 2016-06-09 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Circulation Research，2015年，Vol. 117，pp. 576-584
JAMA，2012年，Vol. 308, No. 22，pp. 2369-2379
RBMOnline，2008年，Vol. 16, No. 6，pp. 898-905

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7491964B2 (ja) 2016-11-11 2024-05-28 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法

Also Published As

Publication number Publication date
EP3538114A1 (fr) 2019-09-18
US20190290698A1 (en) 2019-09-26
CA3043594A1 (fr) 2018-05-17
IL266561A (en) 2019-07-31
CN110691600A (zh) 2020-01-14
TWI820753B (zh) 2023-11-01
TW202237819A (zh) 2022-10-01
IL266561B1 (en) 2024-02-01
ZA201903574B (en) 2020-12-23
JP2019534307A (ja) 2019-11-28
AU2017358042A1 (en) 2019-05-30
IL266561B2 (en) 2024-06-01
WO2018089752A1 (fr) 2018-05-17
JP7491964B2 (ja) 2024-05-28
TW201831681A (zh) 2018-09-01
KR20190084091A (ko) 2019-07-15
CN110691600B (zh) 2024-04-16
JP2022106755A (ja) 2022-07-20

Similar Documents

Publication Publication Date Title
JP7276664B2 (ja) 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
EP3134120B1 (fr) Compositions et méthodes pour le traitement de troubles liés aux cytokines
CN114616324A (zh) 包含调节性t细胞的组合物及其制备和使用方法
JP2023036949A (ja) ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
WO2014089397A1 (fr) Compositions et méthodes de traitement et de prévention de la fibrose pulmonaire
JP2024511052A (ja) 濃縮された制御性ｔ細胞の集団及びその産生方法
NZ794290A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
NZ794292A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
Marvasti Aging and Heart Failure Alter the Bone Marrow Derived Inflammatory Response and Impair Cardiac Remodeling Following Myocardial Infarction
Foyle Characterisation of human dental pulp stem cells in an animal model of multiple sclerosis
US20120294834A1 (en) Regeneration of, reestablishing function in and replacing microvasculature in organs and tissues
JP2023522931A (ja) ポテンシーアッセイ
Cain Regulating emergency granulopoiesis
CN117377755A (zh) 包含调节性t细胞的组合物及其使用方法
Moore et al. Stem cell transplantation for autoimmune diseases
Binesh Marvasti Aging and Heart Failure Alter the Bone Marrow Derived Inflammatory Response and Impair Cardiac Remodeling Following Myocardial Infarction
JP2008536511A (ja) ＣＤ８Ｔ細胞の活性化方法｛ＭｅｔｈｏｄＦｏｒＡｃｔｉｖａｔｉｎｇＣＤ８ＴＣｅｌｌｓ｝
Sala Mesenchymal stem cells: mechanisms involved in the treatment of Inflammatory Bowel Disease
Iachininoto et al. Physicians Poster Sessions
US20120014926A1 (en) Activation of Precursor Cells for Cell Therapy
Manuelpillai et al. Human Amniotic Epithelial Cell Transplantation Induces Markers of
Ortega Autoregulatory CD8 T-Cells Modulate CNS Autoimmune Disease by Targeting Encephalitogenic CD4 T-Cells

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230117

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230220

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230418

R150 Certificate of patent or registration of utility model

Ref document number: 7276664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150